Context Therapeutics Inc. (NASDAQ:CNTX) Sees Significant Growth in Short InterestMarket Beat·Jul 12 at 09:40 PMCNTX-5.09%OWL+1.34%
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Unusual Whales·Jul 10 at 03:22 PMCNTX-5.09%
Context Therapeutics grants new hire stock options for 146,000 shares at $0.7 eachPUBT·Jul 10 at 03:05 PMCNTX-5.09%
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes | CNTX Stock NewsStockTitan·Jul 6 at 07:07 AMCNTX-5.09%
Context Therapeutics shareholders approve increase in authorized common shares to 300 millionPUBT·Jun 26 at 03:08 PMCNTX-5.09%
Boris Peaker Reiterates Buy on Context Therapeutics, Maintains $7 Price Target on Promising CTIM-76 Data and Attractive Risk/RewardTip Ranks·Jun 15 at 12:55 PMCNTX-5.09%
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga_article·Jun 15 at 12:05 PMCYPH-2.03%GNPX+3.81%
Charles Zhu Reiterates Buy on Context Therapeutics, Citing Encouraging CTIM-76 Efficacy, Favorable Safety, and De‑Risked Development OutlookTip Ranks·Jun 15 at 11:35 AMCNTX-5.09%
CNTX: CTIM-76 achieved a 29% response rate and low-grade CRS in late-line ovarian cancer patientsQuartr·Jun 15 at 10:24 AMCNTX-5.09%
Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Studybenzinga_article·Jun 15 at 10:10 AMCNTX-5.09%
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76 | CNTX Stock NewsStockTitan·Jun 14 at 09:30 PMCNTX-5.09%
